ICU Medical, Inc. (NASDAQ:ICUI) Stake Lifted by Geode Capital Management LLC

Geode Capital Management LLC raised its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 9.6% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 546,954 shares of the medical instruments supplier’s stock after buying an additional 48,106 shares during the quarter. Geode Capital Management LLC owned approximately 2.23% of ICU Medical worth $99,687,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Hexagon Capital Partners LLC increased its holdings in shares of ICU Medical by 162.7% in the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 122 shares during the period. Allworth Financial LP grew its position in ICU Medical by 100.0% in the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 100 shares during the last quarter. Innealta Capital LLC acquired a new stake in shares of ICU Medical in the second quarter valued at approximately $32,000. Venturi Wealth Management LLC raised its holdings in shares of ICU Medical by 1,510.0% during the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock valued at $59,000 after buying an additional 302 shares during the last quarter. Finally, Point72 Hong Kong Ltd acquired a new position in shares of ICU Medical during the third quarter worth approximately $72,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Price Performance

Shares of ICU Medical stock opened at $154.07 on Thursday. ICU Medical, Inc. has a 52 week low of $86.80 and a 52 week high of $196.26. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The stock has a market cap of $3.77 billion, a PE ratio of -33.71 and a beta of 0.62. The company’s 50-day moving average price is $169.78 and its two-hundred day moving average price is $152.41.

Wall Street Analyst Weigh In

Several analysts recently commented on ICUI shares. KeyCorp raised their target price on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, November 13th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Raymond James raised their target price on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Finally, Jefferies Financial Group raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target for the company in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $199.67.

Insider Buying and Selling

In other news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $162.91, for a total transaction of $1,954,920.00. Following the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $17,039,245.63. The trade was a 10.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Christian B. Voigtlander sold 1,430 shares of the stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $158.00, for a total value of $225,940.00. The disclosure for this sale can be found here. Insiders have sold 40,364 shares of company stock worth $6,869,878 in the last ninety days. 6.70% of the stock is currently owned by corporate insiders.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.